Sean P.  Nolan net worth and biography

Sean Nolan Biography and Net Worth

Sean P. Nolan is a businessperson who has been at the head of 6 different companies. Mr. Nolan occupies the position of Executive Chairman for Istari Oncology, Inc., Chairman of Encoded Therapeutics, Inc., Chairman of Taysha Gene Therapies, Inc. and Chairman & President at Nolan Capital LLC.

He is also on the board of Ventas, Inc., Affinia Therapeutics, Inc. and Social Capital Suvretta Holdings Corp. II.

He previously was Chief Commercial Officer for Reata Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Novartis Gene Therapies, Inc., President & Chief Commercial Officer at Lundbeck, Inc., Chief Business Officer & Executive Vice President at InterMune, Inc. and Vice President-Marketing & Sales Operations at OVATION Pharmaceuticals, Inc.

Mr. Nolan received an undergraduate degree from John Carroll University.

What is Sean P. Nolan's net worth?

The estimated net worth of Sean P. Nolan is at least $4.79 million as of August 16th, 2023. Mr. Nolan owns 1,535,545 shares of Taysha Gene Therapies stock worth more than $4,790,900 as of March 28th. This net worth estimate does not reflect any other assets that Mr. Nolan may own. Additionally, Mr. Nolan receives a salary of $674,000.00 as Director at Taysha Gene Therapies. Learn More about Sean P. Nolan's net worth.

How old is Sean P. Nolan?

Mr. Nolan is currently 56 years old. There are 2 older executives and no younger executives at Taysha Gene Therapies. The oldest executive at Taysha Gene Therapies is Dr. Sukumar Nagendran M.D., President, Head of Research & Development and Director, who is 57 years old. Learn More on Sean P. Nolan's age.

What is Sean P. Nolan's salary?

As the Director of Taysha Gene Therapies, Inc., Mr. Nolan earns $674,000.00 per year. The highest earning executive at Taysha Gene Therapies is Mr. Kamran Alam CPA, M.B.A., CFO & Corporate Secretary, who commands a salary of $703,610.00 per year. Learn More on Sean P. Nolan's salary.

How do I contact Sean P. Nolan?

The corporate mailing address for Mr. Nolan and other Taysha Gene Therapies executives is 2280 Inwood Road, DALLAS TX, 75235. Taysha Gene Therapies can also be reached via phone at 214-612-0000 and via email at [email protected]. Learn More on Sean P. Nolan's contact information.

Has Sean P. Nolan been buying or selling shares of Taysha Gene Therapies?

Sean P. Nolan has not been actively trading shares of Taysha Gene Therapies during the last quarter. Most recently, on Wednesday, August 16th, Sean P. Nolan bought 444,444 shares of Taysha Gene Therapies stock. The stock was acquired at an average cost of $0.90 per share, with a total value of $399,999.60. Following the completion of the transaction, the chief executive officer now directly owns 1,535,545 shares of the company's stock, valued at $1,381,990.50. Learn More on Sean P. Nolan's trading history.

Who are Taysha Gene Therapies' active insiders?

Taysha Gene Therapies' insider roster includes Kamran Alam (CFO), Phillip Donenberg (Director), Paul Manning (Director), Sean Nolan (Director), and R.A. Session, II (CEO). Learn More on Taysha Gene Therapies' active insiders.

Are insiders buying or selling shares of Taysha Gene Therapies?

In the last twelve months, Taysha Gene Therapies insiders bought shares 5 times. They purchased a total of 17,405,000 shares worth more than $15,736,400.00. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 419,689 shares worth more than $351,334.11. The most recent insider tranaction occured on November, 17th when Major Shareholder Paul B Manning bought 100,000 shares worth more than $163,000.00. Insiders at Taysha Gene Therapies own 2.3% of the company. Learn More about insider trades at Taysha Gene Therapies.

Information on this page was last updated on 11/17/2023.

Sean P. Nolan Insider Trading History at Taysha Gene Therapies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2023Buy444,444$0.90$399,999.601,535,545View SEC Filing Icon  
5/20/2021Buy1,170$22.35$26,149.501,170View SEC Filing Icon  
See Full Table

Sean P. Nolan Buying and Selling Activity at Taysha Gene Therapies

This chart shows Sean P Nolan's buying and selling at Taysha Gene Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Taysha Gene Therapies Company Overview

Taysha Gene Therapies logo
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Read More

Today's Range

Now: $3.06
Low: $3.00
High: $3.30

50 Day Range

MA: $2.15
Low: $1.43
High: $3.25

2 Week Range

Now: $3.06
Low: $0.50
High: $3.89

Volume

1,112,522 shs

Average Volume

2,762,063 shs

Market Capitalization

$572.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31